Home   >  
Neuro Signaling Pathway
  • GPCR/G Protein
  >  
Dopamine Receptor
  >   Dexpramipexole
Dexpramipexole Chemical Structure

Dexpramipexole

Data Sheet For research use only. Not for human use.
Cat. No. :BCP12512CAS No. :104632-28-2Purity:98%
 Tel: 0086-17754423994   or   orders@biochempartner.com
Real-Time Inquiry ×

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • Chemical Properties&Biological Activity
CAS No. 104632-28-2 Cat. No. BCP12512
Name Dexpramipexole
Synonyms (R)-Pramipexole;KNS-760704; KNS 760704; KNS760704;R-(+)-Pramipexole;
SMILES
Chemical Name
Formula C10H17N3S M. Wt 211.33
Purity 98% Storage Store at 4-8°C
Description Dexpramipexole, also known as KNS-760704 and (R)-Pramipexole, is under development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS. Dexpramipexole is a low molecular weight, water-soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics, and has been shown to be well tolerated in human subject testing. KNS-760704 is the enantiomer of pramipexole, and has been shown to improve mitochondrial function and to confer significant cellular protection in neurons under stress. A 2010 Phase II clinical trial involving 102 patients showed a slowing of ALS disease progression.[5] In January 2013, Biogen Idec announced that it was discontinuing its development of dexpramipexole in ALS due to lack of efficacy in a Phase III study.
  • Quality Control&Technical Support
In the process of purchasing and using Biochempartner products, you can consult us if you have any problems: orders@biochempartner.com. We will try our best to solve all your doubts.

Recommend Products

More >

Tags:Dexpramipexole supplier,Dexpramipexole purchase,Dexpramipexole manufacturer,Dexpramipexole distributor,Dexpramipexole cost,Dexpramipexole buy,Dexpramipexole for sale

0086-13720134139